vs
Side-by-side financial comparison of AbbVie (ABBV) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $493.8M, roughly 33.7× Pediatrix Medical Group, Inc.). AbbVie runs the higher net margin — 10.9% vs 6.8%, a 4.1% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs -1.7%). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs -0.1%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ABBV vs MD — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $493.8M |
| Net Profit | $1.8B | $33.7M |
| Gross Margin | 72.6% | — |
| Operating Margin | 27.3% | 9.9% |
| Net Margin | 10.9% | 6.8% |
| Revenue YoY | 10.0% | -1.7% |
| Net Profit YoY | 8354.5% | 10.5% |
| EPS (diluted) | $1.02 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $493.8M | ||
| Q3 25 | $15.8B | $492.9M | ||
| Q2 25 | $15.4B | $468.8M | ||
| Q1 25 | $13.3B | $458.4M | ||
| Q4 24 | $15.1B | $502.4M | ||
| Q3 24 | $14.5B | $511.2M | ||
| Q2 24 | $14.5B | $504.3M | ||
| Q1 24 | $12.3B | $495.1M |
| Q4 25 | $1.8B | $33.7M | ||
| Q3 25 | $186.0M | $71.7M | ||
| Q2 25 | $938.0M | $39.3M | ||
| Q1 25 | $1.3B | $20.7M | ||
| Q4 24 | $-22.0M | $30.5M | ||
| Q3 24 | $1.6B | $19.4M | ||
| Q2 24 | $1.4B | $-153.0M | ||
| Q1 24 | $1.4B | $4.0M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | 9.9% | ||
| Q3 25 | 12.1% | 13.8% | ||
| Q2 25 | 31.7% | 12.8% | ||
| Q1 25 | 28.0% | 7.0% | ||
| Q4 24 | -9.9% | 7.8% | ||
| Q3 24 | 26.5% | 6.6% | ||
| Q2 24 | 27.6% | -31.3% | ||
| Q1 24 | 22.7% | 3.2% |
| Q4 25 | 10.9% | 6.8% | ||
| Q3 25 | 1.2% | 14.5% | ||
| Q2 25 | 6.1% | 8.4% | ||
| Q1 25 | 9.6% | 4.5% | ||
| Q4 24 | -0.1% | 6.1% | ||
| Q3 24 | 10.8% | 3.8% | ||
| Q2 24 | 9.5% | -30.3% | ||
| Q1 24 | 11.1% | 0.8% |
| Q4 25 | $1.02 | $0.40 | ||
| Q3 25 | $0.10 | $0.84 | ||
| Q2 25 | $0.52 | $0.46 | ||
| Q1 25 | $0.72 | $0.24 | ||
| Q4 24 | $-0.03 | $0.37 | ||
| Q3 24 | $0.88 | $0.23 | ||
| Q2 24 | $0.77 | $-1.84 | ||
| Q1 24 | $0.77 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $375.2M |
| Total DebtLower is stronger | $58.9B | $570.5M |
| Stockholders' EquityBook value | $-3.3B | $865.9M |
| Total Assets | $134.0B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $375.2M | ||
| Q3 25 | $5.7B | $340.1M | ||
| Q2 25 | $6.5B | $224.7M | ||
| Q1 25 | $5.2B | $99.0M | ||
| Q4 24 | $5.6B | $229.9M | ||
| Q3 24 | $7.3B | $103.8M | ||
| Q2 24 | $13.2B | $19.4M | ||
| Q1 24 | $18.1B | $8.0M |
| Q4 25 | $58.9B | $570.5M | ||
| Q3 25 | $63.0B | $577.2M | ||
| Q2 25 | $63.0B | $583.9M | ||
| Q1 25 | $64.5B | $590.5M | ||
| Q4 24 | $60.3B | $597.1M | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
| Q4 25 | $-3.3B | $865.9M | ||
| Q3 25 | $-2.6B | $890.7M | ||
| Q2 25 | $-183.0M | $833.8M | ||
| Q1 25 | $1.4B | $789.2M | ||
| Q4 24 | $3.3B | $764.9M | ||
| Q3 24 | $6.0B | $732.5M | ||
| Q2 24 | $6.8B | $706.5M | ||
| Q1 24 | $8.0B | $856.2M |
| Q4 25 | $134.0B | $2.2B | ||
| Q3 25 | $133.9B | $2.2B | ||
| Q2 25 | $137.2B | $2.1B | ||
| Q1 25 | $136.2B | $2.0B | ||
| Q4 24 | $135.2B | $2.2B | ||
| Q3 24 | $143.4B | $2.1B | ||
| Q2 24 | $141.9B | $2.0B | ||
| Q1 24 | $148.9B | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | 45.44× | 0.75× | ||
| Q4 24 | 18.15× | 0.78× | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $114.1M |
| Free Cash FlowOCF − Capex | $4.9B | — |
| FCF MarginFCF / Revenue | 29.4% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.87× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $114.1M | ||
| Q3 25 | $7.0B | $137.3M | ||
| Q2 25 | $5.2B | $137.2M | ||
| Q1 25 | $1.6B | $-117.5M | ||
| Q4 24 | $7.0B | $133.0M | ||
| Q3 24 | $5.4B | $91.8M | ||
| Q2 24 | $2.3B | $107.0M | ||
| Q1 24 | $4.0B | $-125.2M |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 2.87× | 3.39× | ||
| Q3 25 | 37.76× | 1.91× | ||
| Q2 25 | 5.49× | 3.49× | ||
| Q1 25 | 1.27× | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | 3.49× | 4.72× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
